94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1566202
This article is part of the Research Topic Bispecific Antibodies and their Conjugates in Solid Tumors and Hematological Malignancies View all articles
Bispecific Antibodies in Immunotherapy for Acute Leukemia: Latest Updates from the 66th Annual Meeting of the American Society of Hematology, 2024
Provisionally accepted
Weijie Cao 1
Shuhan Ma 2
Lijie Han 1
Haizhou Xing 1
Li Yingmei 1
Zhongxing Jiang 1
Xue-jun Guo 2
Jifeng Yu 1*- 1 First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- 2 Puyang Oil Field General Hospital, Puyang, Henan, China
Bispecific antibodies (BsAbs) are cutting-edge immunotherapy agents that can bind two distinct antigens or epitopes simultaneously. They hold significant potential in targeting leukemic cell markers and activating immune cells like T cells or NK cells to eliminate malignant cells. BsAb treatments showed encouraging outcomes for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In relapsed/refractory (R/R) ALL, BsAbs improved overall survival (OS) and achieved measurable residual disease (MRD) negativity in most patients. Blinatumomab plus standard chemotherapy or in combination with other treatments, such as Mini-Hyper-CVD and Inotuzumab Ozogamicin, improved disease-free survival (DFS) in B-ALL.In AML and related conditions, novel BsAbs like AFM28 (CD123xCD16A) and Vibecotamab (CD123xCD3) showed promising efficacy in heavily pretreated R/R AML and in MDS/CMML following the failure of treatment with hypomethylating agents (HMA). The meeting underscored the transformative potential of BsAbs, especially in ALL-focused trials, with ongoing research aiming to evaluate their safety and efficacy in broader patient populations and combination regimens. This summary highlights the latest progress in BsAb-based immunotherapy presented at the ASH 2024 meeting, held from December 7-10 in San Diego, California.
Keywords: bispecific antibodies, Acute Lymphoblastic Leukemia, Acute myeloid eukemia, myelodysplastic syndrome (MDS), Immunotherapy
Received: 24 Jan 2025; Accepted: 20 Mar 2025.
Copyright: © 2025 Cao, Ma, Han, Xing, Yingmei, Jiang, Guo and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jifeng Yu, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.